109 related articles for article (PubMed ID: 28922853)
1. A Rationale for Targeting Extracellular Regulated Kinases ERK1 and ERK2 in Glioblastoma.
Hannen R; Hauswald M; Bartsch JW
J Neuropathol Exp Neurol; 2017 Oct; 76(10):838-847. PubMed ID: 28922853
[TBL] [Abstract][Full Text] [Related]
2. A novel treatment for glioblastoma: integrin inhibition.
Chamberlain MC; Cloughsey T; Reardon DA; Wen PY
Expert Rev Neurother; 2012 Apr; 12(4):421-35. PubMed ID: 22449214
[TBL] [Abstract][Full Text] [Related]
3. Necroptosis: a novel therapeutic target for glioblastoma.
Jiang YG; Peng Y; Koussougbo KS
Med Hypotheses; 2011 Mar; 76(3):350-2. PubMed ID: 21075544
[TBL] [Abstract][Full Text] [Related]
4. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
5. Both mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinases (ERK) 1/2 and phosphatidylinositide-3-OH kinase (PI3K)/Akt pathways regulate activation of E-twenty-six (ETS)-like transcription factor 1 (Elk-1) in U138 glioblastoma cells.
Mut M; Lule S; Demir O; Kurnaz IA; Vural I
Int J Biochem Cell Biol; 2012 Feb; 44(2):302-10. PubMed ID: 22085529
[TBL] [Abstract][Full Text] [Related]
6. Chitinase 3-like protein 2 (CHI3L2, YKL-39) activates phosphorylation of extracellular signal-regulated kinases ERK1/ERK2 in human embryonic kidney (HEK293) and human glioblastoma (U87 MG) cells.
Areshkov PA; Kavsan VM
Tsitol Genet; 2010; 44(1):3-9. PubMed ID: 20201406
[TBL] [Abstract][Full Text] [Related]
7. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid.
Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M
Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261
[TBL] [Abstract][Full Text] [Related]
8. [New therapeutic approaches in glioblastomas].
Le Guilloux J; Carpentier AF
Rev Neurol (Paris); 2008; 164(6-7):554-9. PubMed ID: 18565354
[TBL] [Abstract][Full Text] [Related]
9. Region- or state-related differences in expression and activation of extracellular signal-regulated kinases (ERKs) in naïve and pain-experiencing rats.
Guo SW; Liu MG; Long YL; Ren LY; Lu ZM; Yu HY; Hou JF; Li H; Gao CY; Cui XY; An YY; Li J; Zhao LF; Chen J
BMC Neurosci; 2007 Jul; 8():53. PubMed ID: 17650295
[TBL] [Abstract][Full Text] [Related]
10. Fas-induced expression of chemokines in human glioma cells: involvement of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase.
Choi C; Xu X; Oh JW; Lee SJ; Gillespie GY; Park H; Jo H; Benveniste EN
Cancer Res; 2001 Apr; 61(7):3084-91. PubMed ID: 11306491
[TBL] [Abstract][Full Text] [Related]
11. Dual blockage of STAT3 and ERK1/2 eliminates radioresistant GBM cells.
Xie B; Zhang L; Hu W; Fan M; Jiang N; Duan Y; Jing D; Xiao W; Fragoso RC; Lam KS; Sun LQ; Li JJ
Redox Biol; 2019 Jun; 24():101189. PubMed ID: 30986607
[TBL] [Abstract][Full Text] [Related]
12. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors.
Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG
Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676
[TBL] [Abstract][Full Text] [Related]
13. PEA-15 inhibits tumor cell invasion by binding to extracellular signal-regulated kinase 1/2.
Glading A; Koziol JA; Krueger J; Ginsberg MH
Cancer Res; 2007 Feb; 67(4):1536-44. PubMed ID: 17308092
[TBL] [Abstract][Full Text] [Related]
14. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.
Albanell J; Codony-Servat J; Rojo F; Del Campo JM; Sauleda S; Anido J; Raspall G; Giralt J; Roselló J; Nicholson RI; Mendelsohn J; Baselga J
Cancer Res; 2001 Sep; 61(17):6500-10. PubMed ID: 11522647
[TBL] [Abstract][Full Text] [Related]
15. Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical Evidence.
Mecca C; Giambanco I; Donato R; Arcuri C
Dis Markers; 2018; 2018():9230479. PubMed ID: 30662577
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway.
Mhaidat NM; Zhang XD; Jiang CC; Hersey P
Clin Cancer Res; 2007 Feb; 13(4):1308-14. PubMed ID: 17317842
[TBL] [Abstract][Full Text] [Related]
17. The EGFRvIII variant in glioblastoma multiforme.
Gan HK; Kaye AH; Luwor RB
J Clin Neurosci; 2009 Jun; 16(6):748-54. PubMed ID: 19324552
[TBL] [Abstract][Full Text] [Related]
18. Adiponectin as novel regulator of cell proliferation in human glioblastoma.
Porcile C; Di Zazzo E; Monaco ML; D'Angelo G; Passarella D; Russo C; Di Costanzo A; Pattarozzi A; Gatti M; Bajetto A; Zona G; Barbieri F; Oriani G; Moncharmont B; Florio T; Daniele A
J Cell Physiol; 2014 Oct; 229(10):1444-54. PubMed ID: 24648185
[TBL] [Abstract][Full Text] [Related]
19. New Directions in the Treatment of Glioblastoma.
Reitman ZJ; Winkler F; Elia AEH
Semin Neurol; 2018 Feb; 38(1):50-61. PubMed ID: 29548052
[TBL] [Abstract][Full Text] [Related]
20. Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review.
Anjum K; Shagufta BI; Abbas SQ; Patel S; Khan I; Shah SAA; Akhter N; Hassan SSU
Biomed Pharmacother; 2017 Aug; 92():681-689. PubMed ID: 28582760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
